Tag Archive for: Capvaxive

CDC backs Merck’s Capvaxive, tees up pneumococcal competition with Pfizer

Unlike the current commercially available pneumococcal vaccines—including its top competitor, Pfizer’s Prevnar 20—Capvaxive covers eight unique serotypes that together account for around 27% of IPD cases in patients 50 years and older, and approximately 30% of cases in seniors 65 years and older.

Read more
/by

Merck wins FDA approval for first pneumococcal vaccine designed for adults

, ,

The FDA on Monday greenlit Merck’s 21-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.

Read more
/by